Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Aurora Cannabis IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs IDEXX Laboratories, Inc. — how do they compare? Aurora Cannabis Inc trades at $3.79 (market cap $223.59M), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 206.7× Aurora Cannabis Inc's market cap, and Aurora Cannabis Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.

ACBIDXX
Market Cap
$223.59M$46.22B
Sector
HealthHealth
52-Week High
$6.23$766.68
52-Week Low
$2.58$526.44
Enterprise Value
$168.09M$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $3.82, up 32.18% amid Curaleaf's hostile takeover bid offering a 45% premium. The stock shows mixed technical signals with neutral RSI but bearish moving averages. Fundamentally, ACB achieved profitability in 2025 with $1.59M net income after years of losses, though 2026 projections show renewed negative margins. Revenue grew 27% year-over-year to $343M, but the company faces significant execution risks in a competitive cannabis market.

The takeover bid creates near-term upside potential to $4 per share, but standalone prospects remain challenged by negative profitability projections and competitive pressures. Investors face a binary outcome: accept the premium offer or risk ACB's volatile standalone execution amid declining 2026 revenue and negative margins.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX